中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 39 Issue 12
Dec.  2023
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(12): 2817-2823

Effect of depression on response to ursodeoxycholic acid and the occurrence of liver cirrhosis in patients with primary biliary cholangitis

DOI: 10.3969/j.issn.1001-5256.2023.12.011

  • Department of Gastroenterology and Hepatology，General Hospital，Tianjin Medical University，Tianjin 300052，China

Research funding:

National Natural Science Foundation of China (82170558);

National Natural Science Foundation of China (81860109)

More Information
  • Corresponding author: ZHOU Lu， lzhou01@tmu.edu.cn （ORCID： 0000-0002-0424-7348）
  • Received Date: 2023-05-15
  • Accepted Date: 2023-06-08
  • Published Date: 2023-12-12
    Abstract
  •   Objective  Depression is common in patients with primary biliary cholangitis （PBC）， but the role of depression in disease progression remains unclear. This study aims to investigate the association between depression and treatment response and the impact of depression on liver cirrhosis in PBC patients.  Methods  A retrospective analysis was performed for the clinical data of 141 patients with PBC who attended the outpatient service of autoimmune liver diseases in General Hospital of Tianjin Medical University from January 2018 to December 2020 and received standard ursodeoxycholic acid （UDCA） monotherapy for 1 year， and 170 healthy controls， matched for age and sex， who underwent physical examination in Physical Examination Center were enrolled as healthy control group. Patient Health Questionnaire-9 （PHQ-9） was used to evaluate depressive state in the patients with PBC and the healthy controls. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical data between two groups. The binary logistic regression model and the decision tree model were used to analyze the influencing factors for liver cirrhosis in patients with PBC， as well as the influence of depression and the HLA-DRB1 gene on liver cirrhosis. The receiver operating characteristic （ROC） curve， the area under the ROC curve （AUC）， and goodness of fit were used to evaluate model performance. All 13 variables were used to establish a classification and regression tree （CART） model， i.e.， age， sex， PHQ-9 score， the DRB1*03∶01 gene， and the serum levels of alanine aminotransferase， aspartate aminotransferase， alkaline phosphatase （ALP）， gamma-glutamyl transpeptidase （GGT）， total bilirubin， immunoglobulin G， immunoglobulin M （IgM）， C3， and C4. The indications including AUC， sensitivity， and specificity were used to evaluate the performance of CART model in the model cohort.  Results  Compared with the normal control group， the PBC group had a significantly higher proportion of the patients with depression （53.9% vs 15.3%， χ2=57.836， P<0.001）. Compared with the PBC patients without depression， the PBC patients with depression had a significantly poorer response to UDCA treatment （χ2=7.549， P=0.006） and significant increases in the serum levels of ALP （Z=-2.157， P=0.031）， GGT （Z=-2.180， P=0.029）， and IgM （Z=-2.000， P=0.046）. Compared with the PBC patients without depression， the PBC patients carrying the HLA-DRB1*03∶01 allele had a significant increase in the risk of liver cirrhosis （P<0.001）. The binary logistic regression model analysis showed that PHQ-9 score （OR=1.148， 95%CI： 1.050 — 1.255， P=0.002）， the HLA-DRB1*03∶01 gene （OR=5.150， 95%CI： 1.362 — 19.478， P=0.016）， age （OR=1.057， 95%CI： 1.009 — 1.106， P=0.018）， and serum ALP level （OR=1.009， 95%CI： 1.001 — 1.017， P=0.020） were independent risk factors for liver cirrhosis in patients with PBC. The decision tree analysis showed that PHQ-9 score ≥3.5 was also a risk factor for liver cirrhosis in PBC patients.  Conclusion  Depression is associated with poor treatment response in patients with PBC， and it is an independent risk factor for liver cirrhosis in patients with PBC. This study highlights the important clinical significance of the identification and early management of depressive state in patients with PBC.

     

    • FullText(HTML)
    • References(28)
  • [1]
    CORDELL HJ, FRYETT JJ, UENO K, et al. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs[J]. J Hepatol, 2021, 75( 3): 572- 581. DOI: 10.1016/j.jhep.2021.04.055.
    [2]
    WONG GL, LAW FM, WONG VW, et al. Health-related quality of life in Chinese patients with primary biliary cirrhosis[J]. J Gastroenterol Hepatol, 2008, 23( 4): 592- 598. DOI: 10.1016/j.jhep.2021.04.055.
    [3]
    BIAGINI MR, TOZZI A, MILANI S, et al. Fatigue in primary biliary cirrhosis: a possible role of comorbidities[J]. Eur J Gastroenterol Hepatol, 2008, 20( 2): 122- 126. DOI: 10.1097/MEG.0b013e3282f1cbda.
    [4]
    SHAHEEN AA, KAPLAN GG, ALMISHRI W, et al. The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes[J]. PLoS One, 2018, 13( 4): e0194839. DOI: 10.1371/journal.pone.0194839.
    [5]
    BUGANZA-TORIO E, MITCHELL N, ABRALDES JG, et al. Depression in cirrhosis-a prospective evaluation of the prevalence, predictors and development of a screening nomogram[J]. Aliment Pharmacol Ther, 2019, 49( 2): 194- 201. DOI: 10.1111/apt.15068.
    [6]
    KRONSTEN VT, TRANAH TH, PARIANTE C, et al. Gut-derived systemic inflammation as a driver of depression in chronic liver disease[J]. J Hepatol, 2022, 76( 3): 665- 680. DOI: 10.1016/j.jhep.2021.11.008.
    [7]
    VOS T, BARBER RM, BELL B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990—2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 386( 9995): 743- 800. DOI: 10.1016/S0140-6736(15)60692-4.
    [8]
    MULLISH BH, KABIR MS, THURSZ MR, et al. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation[J]. Aliment Pharmacol Ther, 2014, 40( 8): 880- 892. DOI: 10.1111/apt.12925.
    [9]
    HARMS MH, de VEER RC, LAMMERS WJ, et al. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis[J]. Gut, 2020, 69( 8): 1502- 1509. DOI: 10.1136/gutjnl-2019-319057.
    [10]
    HIRSCHFIELD GM, LIU X, XU C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants[J]. N Engl J Med, 2009, 360( 24): 2544- 2555. DOI: 10.1056/NEJMoa0810440.
    [11]
    LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2019, 69( 1): 394- 419. DOI: 10.1002/hep.30145.
    [12]
    PARÉS A, CABALLERÍA L, RODÉS J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid[J]. Gastroenterology, 2006, 130( 3): 715- 720. DOI: 10.1053/j.gastro.2005.12.029.
    [13]
    NEGERI ZF, LEVIS B, SUN Y, et al. Accuracy of the Patient Health Questionnaire-9 for screening to detect major depression: updated systematic review and individual participant data meta-analysis[J]. BMJ, 2021, 375: n2183. DOI: 10.1136/bmj.n2183.
    [14]
    GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/S0140-6736(21)01374-X.
    [15]
    SCHRAMM C, WAHL I, WEILER-NORMANN C, et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis[J]. J Hepatol, 2014, 60( 3): 618- 624. DOI: 10.1016/j.jhep.2013.10.035.
    [16]
    LIAO J, KANG J, LI F, et al. A cross-sectional study on the association of anxiety and depression with the disease activity of systemic lupus erythematosus[J]. BMC Psychiatry, 2022, 22( 1): 591. DOI: 10.1186/s12888-022-04236-z.
    [17]
    MICHELSEN B, KRISTIANSLUND EK, SEXTON J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study[J]. Ann Rheum Dis, 2017, 76( 11): 1906- 1910. DOI: 10.1136/annrheumdis-2017-211284.
    [18]
    KOCHAR B, BARNES EL, LONG MD, et al. Depression is associated with more aggressive inflammatory bowel disease[J]. Am J Gastroenterol, 2018, 113( 1): 80- 85. DOI: 10.1038/ajg.2017.423.
    [19]
    ROBERTS AL, KUBZANSKY LD, MALSPEIS S, et al. Association of depression with risk of incident systemic lupus erythematosus in women assessed across 2 decades[J]. JAMA Psychiatry, 2018, 75( 12): 1225- 1233. DOI: 10.1001/jamapsychiatry.2018.2462.
    [20]
    ONUORA S. Depression linked to seronegative RA risk[J]. Nat Rev Rheumatol, 2020, 16( 12): 666. DOI: 10.1038/s41584-020-00532-8.
    [21]
    ANANTHAKRISHNAN AN. Epidemiology and risk factors for IBD[J]. Nat Rev Gastroenterol Hepatol, 2015, 12( 4): 205- 217. DOI: 10.1038/nrgastro.2015.34.
    [22]
    CAUCH-DUDEK K, ABBEY S, STEWART DE, et al. Fatigue in primary biliary cirrhosis[J]. Gut, 1998, 43( 5): 705- 710. DOI: 10.1136/gut.43.5.705.
    [23]
    UMEMURA T, JOSHITA S, ICHIJO T, et al. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis[J]. Hepatology, 2012, 55( 2): 506- 511. DOI: 10.1002/hep.24705.
    [24]
    CZAJA AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis[J]. J Hepatol, 2009, 51( 1): 161- 167. DOI: 10.1016/j.jhep.2009.02.026.
    [25]
    MURATORI P, GRANITO A, QUARNETI C, et al. Autoimmune hepatitis in Italy: the Bologna experience[J]. J Hepatol, 2009, 50( 6): 1210- 1218. DOI: 10.1016/j.jhep.2009.01.020.
    [26]
    KATRINLI S, LORI A, KILARU V, et al. Association of HLA locus alleles with posttraumatic stress disorder[J]. Brain Behav Immun, 2019, 81: 655- 658. DOI: 10.1016/j.bbi.2019.07.016.
    [27]
    LE CLERC S, LOMBARDI L, BAUNE BT, et al. HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders[J]. Sci Rep, 2021, 11( 1): 17823. DOI: 10.1038/s41598-021-97140-7.
    [28]
    BANDINELLI F, BENUCCI M, SALAFFI F, et al. Do new and old biomarkers of early undifferentiated arthritis correlate with arthritis impact measurement scales?[J]. Clin Exp Rheumatol, 2021, 39( 1): 79- 83. DOI: 10.55563/clinexprheumatol/nqqx5k.
    • Relative Articles

  • Relative Articles

    [1]Guozhi WU, Guohong WU, Xianglei ZHANG, Guangzhi DING, Lei WANG. Severe drug-induced hypersensitivity syndrome in patients with liver cirrhosis and epilepsy induced by lamotrigine: A case report[J]. Journal of Clinical Hepatology, 2021, 37(8): 1907-1908. doi: 10.3969/j.issn.1001-5256.2021.08.032
    [2]LI ZhengHong, DONG YuWei, LU LunGen. Risk factors,diagnosis,and updated classification of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2411-2414. doi: 10.3969/j.issn.1001-5256.2020.11.003
    [3]Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043
    [4]Wang CaiBin, Su Yang. Risk factors for posthepatectomy liver failure and related prevention and treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(9): 2119-2124. doi: 10.3969/j.issn.1001-5256.2020.09.048
    [5]Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
    [6]Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
    [7]Bai Xue, Ma ZuoHong, Hao ZhiQiang, Fu XiBo, Jiao Ao, Shang Hai, Hua XiangDong. Research advances in the risk factors for microvascular invasion in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(11): 2578-2581. doi: 10.3969/j.issn.1001-5256.2019.11.042
    [8]Zhang Dan, Feng GuoHe. Current research status of nosocomial infection in patients with severe liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(1): 213-216. doi: 10.3969/j.issn.1001-5256.2019.01.047
    [9]Chang XiuJuan, Lu YinYing, Rong GuangHua, Liu Ze, Chen Yan, Xu GuiLin, Gao XuDong, Lou Min, Wang ChunPing, Yang YongPing, Ceng Zhen. Risk factors for vascular invasion of primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1038-1041. doi: 10.3969/j.issn.1001-5256.2018.05.022
    [10]Lin YunXia, He XiaoBin. Clinical features of drug-induced liver injury and related risk factors[J]. Journal of Clinical Hepatology, 2018, 34(6): 1237-1241. doi: 10.3969/j.issn.1001-5256.2018.06.021
    [11]Jie EnBo, Xuan FengHui, Sun XiaoDong, Sun DaWei, Lu: GuoYue. An analysis of risk factors for early complications after liver transplantation[J]. Journal of Clinical Hepatology, 2018, 34(6): 1282-1288. doi: 10.3969/j.issn.1001-5256.2018.06.030
    [12]Li Ying, Zhan Jing, Wang ZhongFeng. Prognostic factors for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2017, 33(3): 497-501. doi: 10.3969/j.issn.1001-5256.2017.03.020
    [13]Wang FengJiao, Liu MingJiang, Wu RuiHong, Niu JunQi. A multivariate logistic regression analysis of short-term prognosis of patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2017, 33(4): 711-714. doi: 10.3969/j.issn.1001-5256.2017.04.022
    [14]Chen BiHua, Zhang Wei, Wu Pei, Huang Ying. Research advances in risk factors for primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(12): 2088-2092. doi: 10.3969/j.issn.1001-5256.2015.12.024
    [15]Qiao LiNa, Dai GuangRong, Zhang Jin, Shen Ni. An epidemiological survey of prevalence and risk factors for fatty liver disease in adults residing in Yan'an,China[J]. Journal of Clinical Hepatology, 2015, 31(1): 82-87. doi: 10.3969/j.issn.1001-5256.2015.01.018
    [16]Ye ChuanTao, Wei Xin, Zhang Ying. Current status of research on liver innate immunity[J]. Journal of Clinical Hepatology, 2014, 30(9): 846-850. doi: 10.3969/j.issn.1001-5256.2014.09.003
    [17]Yu Zheng, Jia JiDong. Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury[J]. Journal of Clinical Hepatology, 2013, 29(9): 674-677. doi: 10.3969/j.issn.1001-5256.2013.09.010
    [18]Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
    [19]Wang Hong, Wang YingMin, Zhang Bo. Prospective analysis of risk factors for the occurrence of hepatocellular carcinoma in patients with post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(1): 34-35.
    [20]Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(1)

    1. 闫红会，张二娟，徐心红. 半坐卧位深部保留灌肠对肝性脑病患者的影响. 内蒙古医学杂志. 2023(11): 1386-1388+1391 .

    Other cited types(1)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 7.4 %FULLTEXT: 7.4 %META: 89.5 %META: 89.5 %PDF: 3.2 %PDF: 3.2 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.2 %其他: 4.2 %India: 0.2 %India: 0.2 %上海: 3.7 %上海: 3.7 %中卫: 0.2 %中卫: 0.2 %佛山: 0.2 %佛山: 0.2 %北京: 12.0 %北京: 12.0 %南宁: 0.2 %南宁: 0.2 %吉林: 0.7 %吉林: 0.7 %哥伦布: 0.2 %哥伦布: 0.2 %岳阳: 0.2 %岳阳: 0.2 %广州: 0.2 %广州: 0.2 %张家口: 2.2 %张家口: 2.2 %成都: 0.7 %成都: 0.7 %杭州: 0.2 %杭州: 0.2 %泰州: 0.2 %泰州: 0.2 %濮阳: 0.2 %濮阳: 0.2 %芒廷维尤: 42.4 %芒廷维尤: 42.4 %莫斯科: 1.2 %莫斯科: 1.2 %衢州: 0.7 %衢州: 0.7 %西宁: 27.2 %西宁: 27.2 %西安: 0.2 %西安: 0.2 %金华: 0.2 %金华: 0.2 %长春: 1.7 %长春: 1.7 %长治: 0.2 %长治: 0.2 %其他India上海中卫佛山北京南宁吉林哥伦布岳阳广州张家口成都杭州泰州濮阳芒廷维尤莫斯科衢州西宁西安金华长春长治

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (481) PDF downloads(72) Cited by(2)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[3692]YesterdayPV[7162]TodayIP[5396]TodayPV[11605]Online[311]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return